Media stories about VBI Vaccines (NASDAQ:VBIV) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. VBI Vaccines earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 44.9226814689256 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
VBIV stock traded down $0.11 during midday trading on Friday, reaching $3.52. 47,420 shares of the stock were exchanged, compared to its average volume of 115,470. The firm has a market capitalization of $223.47, a P/E ratio of -4.64 and a beta of 2.04. VBI Vaccines has a 52 week low of $3.04 and a 52 week high of $5.17. The company has a quick ratio of 5.26, a current ratio of 5.32 and a debt-to-equity ratio of 0.10.
A number of brokerages recently weighed in on VBIV. Zacks Investment Research upgraded VBI Vaccines from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a research report on Saturday, December 23rd. BidaskClub lowered VBI Vaccines from a “hold” rating to a “sell” rating in a research report on Thursday, December 14th. Finally, Noble Financial restated a “buy” rating on shares of VBI Vaccines in a research report on Friday, March 23rd. Three analysts have rated the stock with a sell rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $8.75.
About VBI Vaccines
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.